Zhou Qian, Su Si, You Wen, Wang Tao, Ren Tong, Zhu Lan
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
National Clinical Research Center for Obstetric and Gynecologic Diseases, Beijing, China.
Dose Response. 2021 Dec 15;19(4):15593258211064744. doi: 10.1177/15593258211064744. eCollection 2021 Oct-Dec.
The systemic inflammation response index (SIRI), a novel and cost-effective serum biomarker, is associated with prognosis in patients with cancer. However, the prognostic value of the SIRI in cancer remains unclear. This study aimed to evaluate the potential role of the SIRI as a prognostic indicator in cancer.
Reports in which the prognostic value of the SIRI in cancer was evaluated were retrieved from electronic databases. The pooled hazard ratio (HR) and 95% confidence interval (CI) were calculated to evaluate the prognostic significance of the SIRI. The odds ratio (OR) was also calculated to explore the association between the SIRI and clinicopathological features.
This study included 30 retrospective studies with 38 cohorts and 10 754 cases. The meta-analysis indicated that a high SIRI was associated with short overall survival (OS) (HR = 2.04, 95% CI = 1.82-2.29, < .001) and disease-free survival (DFS)/recurrence-free survival (RFS)/progression-free survival (PFS) (HR = 2.08, 95% CI = 1.84-2.34, < .001). Subgroup analysis showed that the prognostic value of the SIRI was significant in all kinds of cancer included. Moreover, the SIRI was significantly correlated with sex, tumor size, T stage, N stage, TNM stage, and lymphovascular invasion.
The pretreatment SIRI could be a promising universal prognostic indicator in cancer.
全身炎症反应指数（SIRI）是一种新型且经济高效的血清生物标志物，与癌症患者的预后相关。然而，SIRI在癌症中的预后价值仍不明确。本研究旨在评估SIRI作为癌症预后指标的潜在作用。
从电子数据库中检索评估SIRI在癌症中预后价值的报告。计算合并风险比（HR）和95%置信区间（CI）以评估SIRI的预后意义。还计算比值比（OR）以探讨SIRI与临床病理特征之间的关联。
本研究纳入了30项回顾性研究，共38个队列和10754例病例。荟萃分析表明，高SIRI与总生存期（OS）缩短（HR = 2.04，95% CI = 1.82 - 2.29，P <.001）以及无病生存期（DFS）/无复发生存期（RFS）/无进展生存期（PFS）缩短（HR = 2.08，95% CI = 1.84 - 2.34，P <.001）相关。亚组分析显示，SIRI的预后价值在所有纳入的癌症类型中均具有显著性。此外，SIRI与性别、肿瘤大小、T分期、N分期、TNM分期和脉管侵犯显著相关。
治疗前SIRI可能是一种有前景的癌症通用预后指标。
